tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Protagonist Therapeutics: Strategic Advancements and Promising Data Drive Buy Rating
PremiumRatingsProtagonist Therapeutics: Strategic Advancements and Promising Data Drive Buy Rating
28d ago
Strategic Entry and Innovation: Protagonist Therapeutics’ Potential in the Obesity Market with PN-477
Premium
Ratings
Strategic Entry and Innovation: Protagonist Therapeutics’ Potential in the Obesity Market with PN-477
29d ago
Protagonist Therapeutics: Promising Developments in Obesity Treatment with PN-477 and Strategic Growth Opportunities
Premium
Ratings
Protagonist Therapeutics: Promising Developments in Obesity Treatment with PN-477 and Strategic Growth Opportunities
29d ago
Protagonist Therapeutics’ Rusfertide: Promising Efficacy and Financial Upside Drive Buy Recommendation
PremiumRatingsProtagonist Therapeutics’ Rusfertide: Promising Efficacy and Financial Upside Drive Buy Recommendation
2M ago
Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera
Premium
Ratings
Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera
2M ago
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
Premium
The Fly
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
2M ago
Protagonist Therapeutics: Buy Rating Backed by Promising Clinical Trials and Market Opportunities
PremiumRatingsProtagonist Therapeutics: Buy Rating Backed by Promising Clinical Trials and Market Opportunities
3M ago
Protagonist Therapeutics reports Q1 EPS (19c), consensus 11c
Premium
The Fly
Protagonist Therapeutics reports Q1 EPS (19c), consensus 11c
3M ago
Is PTGX a Buy, Before Earnings?
Premium
Pre-Earnings
Is PTGX a Buy, Before Earnings?
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100